Scientific Misconduct and the Stalled Search for Alzheimer's Cures

The podcast delves into the perplexing lack of progress in treating Alzheimer's disease, despite a significant increase in research funding, now second only to cancer. It posits that a major contributing factor is the long-standing dominance of a single theory, the amyloid cascade hypothesis, which may be fundamentally flawed. The episode uncovers a disturbing pattern of scientific misconduct, including data manipulation and outright fraud, that has potentially misdirected billions of dollars and decades of research efforts, leaving millions affected by the disease without effective remedies. A key distinction is drawn between the natural failures inherent in scientific exploration and deliberate deception. The amyloid cascade hypothesis, which posits beta amyloid plaques as the "first domino" in the disease progression, is critically examined. Neuroscientist Matthew Schrag argues that Alzheimer's is likely a far more complex, multifactorial disease, involving elements like blood vessel pathologies, environmental pollutants, and socioeconomic disparities, rather than a single protein accumulation. The discussion also clarifies the distinct roles of extracellular beta amyloid plaques and intracellular tau protein tangles in neuronal dysfunction. The investigation implicitly calls for a radical shift in how scientific research is funded, conducted, and overseen. It highlights the need for robust, independent scrutiny of research data, rather than relying on institutions to investigate their own alleged misconduct. The episode suggests diversifying research avenues beyond the singular focus on amyloid, exploring alternative hypotheses, and prioritizing preventative measures and care, including addressing known environmental and socioeconomic risk factors. The experience of whistleblowers underscores the personal and professional risks involved in challenging established scientific narratives and corporate interests. The broader implications extend beyond Alzheimer's, touching upon the foundational integrity of scientific enterprise, the ethical responsibilities of researchers, and the accountability of funding bodies like the NIH and FDA. The narrative exposes the vulnerability of public trust when scientific findings are compromised by fraud, and the tragic consequences for patients awaiting cures. It serves as a stark reminder of the systemic challenges in ensuring scientific rigor and transparency, especially when large sums of public money and powerful corporate interests are at stake, advocating for a more open and critical approach to scientific discovery.

No one's getting better with these drugs. Every scientist who works with them, every clinician, will say the same. If they don't, they're lying.

So, is flawed even the right word, or should it be fraud?

Cheaters tend to cheat. When we find clear overt problems in a paper in a group of papers, often it propagates through somebody's entire work.

Unlike cancer, diabetes, heart disease, and myriad other ailments that afflict us, Alzheimer's disease is something that the nation and the world has spent tens of billions of dollars on in recent decades, and yet we have no remedy that arrests or reverses the terrible cognitive decline of the disease.

The problem is one, the idea may not be correct and two, the biology of this is likely much more complicated and I think that this is the primary issue.

By targeting just one very specific factor, I think we're not having a big enough impact on the disease.

You take a substantial risk to engage on a topic like this against a multi-billion dollar company.

It looked visually manipulated. Some of these results had copy and paste type changes where it looked like things had been moved around or duplicated or where the intensity of one part of the image had been adjusted and ultimately a lot of these results, how dark a splodge on the photograph is, is what we ultimately measure to turn it into data. So, changing the intensity of those values changes the underlying data.

To me, this is exactly the wrong approach because you're entrusting the organization that has the most to lose and the least to gain from a robust, complete, and publicly accessible examination of possible misconduct to do that examination.